GoodRx and Lilly Offer Employers a New Path to Zepbound Access

SANTA MONICA, CA – March 06, 2026 – In a significant move to address the soaring costs of popular weight-loss medications, prescription savings platform GoodRx has announced a collaboration with pharmaceutical giant Eli Lilly to offer the GLP-1 drug Zepbound to employers at a fixed price. The new program, facilitated through GoodRx Employer Direct, allows self-insured companies to provide their employees with access to the Zepbound KwikPen for $449 per month, a stark contrast to the drug's list price, which often exceeds $1,000.

This partnership marks a pivotal moment in the rapidly evolving landscape of obesity treatment, creating a new channel for accessing high-demand therapies outside the confines of traditional insurance formularies. By acting as an independent administrator for Lilly’s Employer Connect program, GoodRx is positioning itself as a key intermediary in a market grappling with unprecedented demand and affordability challenges.

A New Prescription for Employer Healthcare Costs

For self-insured employers, the meteoric rise of GLP-1 drugs like Zepbound and its competitor, Wegovy, has presented a significant financial dilemma. While these medications offer promising health outcomes for employees struggling with obesity, their high cost has strained corporate health budgets, forcing many companies to limit or exclude coverage entirely. This new program aims to provide a predictable and manageable solution.

“Employers are navigating rising demand for GLP-1 obesity treatments and need predictable, transparent affordability solutions,” said Laura Jensen, Chief Commercial Officer & President of Pharma Direct at GoodRx, in the company's announcement. The GoodRx Employer Direct model allows companies to opt-in to provide Zepbound at the set $449 price without overhauling their entire health benefits structure. Furthermore, it gives employers the flexibility to further subsidize the cost for their employees at the pharmacy counter, potentially lowering the financial barrier even more.

This approach bypasses the complex and often restrictive nature of traditional pharmacy benefit manager (PBM) formularies, which can involve lengthy approval processes and strict eligibility criteria. By creating a direct, simplified pathway, the program offers a lifeline to employers who want to support employee health but have been deterred by unpredictable costs and administrative hurdles.

GoodRx's Strategic Shift from Discounter to Integrator

This collaboration signals a profound evolution in GoodRx’s business strategy. Long known to consumers as a mobile app for finding prescription drug coupons, the company is now leveraging its platform to become a more deeply integrated player in the healthcare ecosystem. The move positions GoodRx not just as a consumer tool, but as a critical piece of infrastructure connecting pharmaceutical manufacturers, employers, pharmacies, and patients.

The foundation for this program is GoodRx's Pharma Direct platform, which enables drug manufacturers to offer discounted cash prices directly to consumers. The new Employer Direct service builds upon that infrastructure, creating a seamless system where manufacturer pricing and employer contributions are combined in real-time at the point of sale.

Eli Lilly, which has been proactive in creating new access channels like its LillyDirect telehealth and pharmacy service, sees this model as a way to expand the reach of Zepbound. “We're excited to collaborate with organizations that share our commitment to removing friction and providing flexible, transparent solutions for employers to expand access to obesity management medicines for people who need them,” stated Kevin Hern, Senior Vice President of Lilly Employer at Lilly USA.

This strategic pivot could prove lucrative for GoodRx, tapping into the multi-billion dollar GLP-1 market while providing a valuable service to two key stakeholders: manufacturers seeking wider distribution and employers seeking cost control. The company is also offering a branded telemedicine solution, 'GoodRx for Weight Loss,' to create an end-to-end service that includes virtual consultations with licensed providers who can prescribe Zepbound when clinically appropriate.

The Question of Access and Equity

While the program promises expanded access and affordability, it also raises important questions about health equity. For employees of large, self-insured companies that choose to participate, the path to obtaining Zepbound becomes significantly easier and cheaper. However, the model inherently creates a tiered system of access.

Employees at smaller companies, those whose employers are fully insured rather than self-insured, or those whose employers choose not to opt into the program will not benefit from this arrangement. This could widen the existing gap in healthcare access, where an individual's ability to obtain life-changing medication is increasingly dependent on their employer's size and benefits philosophy.

The program highlights the fragmented and complex nature of American drug pricing. A single drug, Zepbound, now has multiple price points depending on the channel: a high list price for the uninsured, a lower but still substantial price through LillyDirect, a negotiated price through traditional insurance, and now a fixed $449 price through this specific employer program. Navigating this maze remains a significant challenge for the average patient.

This model effectively privatizes a portion of the benefits-design process, moving it outside the traditional insurance framework. While it provides a solution for a specific segment of the population, it does not address the systemic issue of high drug prices for the broader market, including individuals covered by Medicare or those in the individual marketplace. Patient advocates will be watching closely to see if such programs ultimately help or hinder the larger goal of equitable access to essential medicines for all who need them.